Kisspeptin-10 Peptide: Sequence, Research Evidence and Batch Testing

Chemical Identity

For general laboratory handling principles, see the Pureline Biolabs peptide reconstitution guide and reconstitution calculator.

PubChem records amidated human Kisspeptin-10 as C63H83N17O14 with a molecular weight of 1302.4 g/mol.[1] Acetate, trifluoroacetate, water or other associated components can change the total composition of supplied material. The batch report should state which form and mass basis it addresses.

How Kisspeptin-10 Relates to KISS1 and Metastin

The human KISS1 gene encodes a larger precursor protein.[8] Processing produces several kisspeptin forms that share the same amidated C-terminal sequence. Kisspeptin-54, historically called metastin, contains 54 residues. Kisspeptin-10 contains its final ten residues and retains receptor activity.[2,3]

The terminal RF-NH2 motif places Kisspeptin-10 within the RFamide peptide group. The NH2 is part of its chemical identity and should remain visible in sequence tables, image labels and analytical records. Writing only YNWNSFGLRF leaves out that modification.

Evidence by Research Level

Kisspeptin-10 research includes receptor assays, cultured-cell experiments, animal models and controlled human physiology studies. These levels should not be merged into one broad claim.

Chemical and Receptor Characterisation

Kisspeptin-10 has a defined ten-residue sequence, C-terminal amide and calculated molecular mass. Studies published in 2001 identified KISS1-derived peptides as ligands for the receptor then known as GPR54.[2,3] The receptor is now generally called KISS1R.

Receptor activation has been studied through intracellular calcium and signalling assays. These tests can show activity in a specified receptor system. They do not establish clinical effectiveness, product purity, exact vial quantity or safety.

In-Vitro Research

Cell studies have examined binding and signalling at human and animal KISS1R. The C-terminal decapeptide contains the shared receptor-active region found across the longer kisspeptin forms.[2,3]

Other laboratory work has examined downstream phospholipase C, intracellular calcium and related signalling pathways. The measured response depends on receptor expression, cell type, concentration and assay design. A cell response cannot define an outcome in a person.

Animal Research

Animal studies have investigated how Kisspeptin-10 relates to gonadotropin-releasing hormone signalling and downstream hormone release. A 2004 study reported responses following central and peripheral administration in rodent models and included in-vitro hypothalamic work.[4]

Animal experiments have also examined reproductive timing, feedback systems and KISS1R signalling in different physiological states. Species, sex, reproductive stage, route and sampling schedule can materially change the result. These findings cannot set a human-use claim.

Human Research

Kisspeptin-10 is unusual among the compounds in this library in that synthetic peptide has been administered to people under controlled research conditions. A 2011 study gave intravenous Kisspeptin-10 to healthy adult men as bolus doses and as continuous infusion. It reported a rapid, dose-dependent rise in serum luteinising hormone and an increase in LH pulse frequency from 0.7 to 1.0 pulses per hour during infusion. Each dosing group contained between four and six men.[5]

A second 2011 study reported that responses differed between men and women and across phases of the menstrual cycle.[6] A 2015 study directly compared Kisspeptin-10, Kisspeptin-54 and gonadotropin-releasing hormone in healthy men.[7]

These studies show that the molecule has been investigated in people, in supervised settings, at defined intravenous doses, in groups small enough to count on two hands. They do not turn retail research material into an authorised medicine, and results from one population or protocol do not transfer automatically to another.

Human studies of Kisspeptin-54 should not be described as Kisspeptin-10 trials. The two peptides share a C-terminal sequence but differ in length, molecular mass, pharmacokinetic behaviour and research protocol.

Evidence Summary

What Is Not Established

No cited study has tested Pureline Biolabs' current Kisspeptin-10 batch for a biological or clinical outcome. Literature about Kisspeptin-10 cannot certify a retail vial.

What Pureline Biolabs Independently Adds

Current Pureline Batch

The values above are taken from the Janoshik report for the sample submitted from batch PLB-010. The reported amount of 10.60mg is above the 10mg labelled vial size; Pureline publishes the measured figure rather than the label figure, in either direction. The certificate names the submitted sample as Kisspeptin; Pureline is standardising its submission labelling to Kisspeptin-10 so that future reports state the decapeptide explicitly rather than the compound family. This certificate reports quantity and chromatographic purity, and does not report a separate sterility, endotoxin or sequence-confirmation result. The panel is updated when Pureline changes to a new batch, and earlier reports are kept under their original batch codes rather than replaced.

The Pureline Testing Standard

Testing Methods Explained

A 99 per cent HPLC result refers to the proportion of detected chromatographic peak area assigned to the target peak under that method. It does not mean that the vial is 99 per cent correctly filled, 99 per cent sterile or 99 per cent safe.

Storage and Traceability

Pureline stores Kisspeptin-10 according to the conditions printed on its label and batch documentation. The cold-chain log records storage and handling while the material remains under Pureline's control. It does not replace analytical testing or prove that no degradation occurred.

Stability depends on peptide form, counterion, residual moisture, container closure, temperature, light and time. A general storage statement cannot provide a validated shelf life for every preparation.

Common Questions